Shree Ganesh Remedies Ltd (SGRL) — shareholding pattern, promoter holding, financials and share price
About Shree Ganesh Remedies Ltd (SGRL)
Shree Ganesh Remedies Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SGRL and on the BSE under scrip code 540737. Its ISIN is INE414Y01015.
Incorporated in 1995, Shree Ganesh Remedies Ltd is a manufacturer of Pharmaceutical Drug Intermediates for API & Fine Chemicals [1]
Shree Ganesh Remedies Limited specializes in manufacturing pharmaceutical intermediates and specialty chemicals, serving global markets. Over 20 years in operation, it has built extensive expertise in complex chemical synthesis, affirming its role as a trusted partner for leading global companies.
The company experienced a challenging quarter with a 22% YoY decline in revenue due to shipment delays and tough European market conditions. Management, however, remains optimistic about a business turnaround in FY27 with new pilot facilities boosting product development.
Listed peers in Pharmaceuticals: Bharat Parenterals Ltd, Kopran Ltd, Hexagon Nutrition Ltd, Remus Pharmaceuticals Ltd, Sigachi Industries Ltd, Anlon Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹687 a share on 10 Jul 2026, Shree Ganesh Remedies Ltd (SGRL) was valued at a price-to-earnings ratio of 49.63x against an industry P/E of 36.41x and a price-to-book of 6.08x on a book value of ₹113.07 per share as of Mar 2025. Solomo computes return on equity of 12.24% and return on capital employed of 15.03% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 49.63x
- Industry P/E
- 36.41x
- P/B
- 6.08x
- EPS (TTM)
- ₹13.84
- Book value / share
- ₹113.07
- ROE
- 12.24%
- ROCE
- 15.03%
- ROA
- 9.26%
- Debt / equity
- 0.26x
- Dividend yield
- 0%
- EBITDA margin
- 34.82%
- 52-week range
- ₹381.1 – ₹759
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Shree Ganesh Remedies Ltd (SGRL) reported revenue of ₹109 crore, net profit of ₹18 crore and earnings per share of ₹13.83. That compares with revenue of ₹109 crore and net profit of ₹23 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹33.2 crore and net profit ₹6.27 crore (consolidated).
| Metric | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 64 | 49 | 126 | 109 | 109 |
| Net profit (₹ cr) | 10 | 10 | 28 | 23 | 18 |
| EPS (₹) | 8.18 | 7.62 | 21.96 | 17.97 | 13.83 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 24.13% | 13.20% | 15.06% | -13.74% |
| Profit growth | 40.34% | 19.13% | 19.91% | -17.93% |
| Stock price CAGR | - | 14% | 19% | 8% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.84% of Shree Ganesh Remedies Ltd (SGRL) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.52%. Market capitalisation was ₹882 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2018.
Largest disclosed public shareholders in Jun 2026: GUNJAN JAYANTIBHAI DHORAJIYA 1.7%, V NAGA RAJA NAIDU 1.27%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.84% | - | - | 0.52% | 27.16% |
| Mar 2026 | 72.84% | - | - | 0% | 27.16% |
| Dec 2025 | 72.8% | - | 0% | 0% | 27.2% |
| Sep 2025 | 72.8% | - | 0.01% | 0% | 27.2% |
| Jun 2025 | 72.8% | - | 0.01% | 0% | 27.2% |
| Mar 2025 | 72.8% | - | 0.01% | - | 27.2% |
| Dec 2024 | 72.8% | - | 0.01% | - | 27.2% |
| Sep 2024 | 70.5% | - | 0.01% | - | 29.5% |